Fragile X syndrome, the search for a targeted treatment

Shimriet Zeidler scopus  -  Erasmus University Medical Center, Netherlands
*Rob Willemsen scopus  -  Erasmus University Medical Center, Netherlands
Received: 17 Dec 2018; Accepted: 23 Mar 2019; Published: 31 Jul 2019; Available online: 27 Jul 2019.
Open Access
Citation Format:
Article Info
Section: Review Articles
Language: EN
Full Text:
Statistics: 201 134


Fragile X syndrome (FXS), the most common monogenetic cause of intellectual disability and autism spectrum disorders, is characterized by behavioral and physical problems. There is currently no adequate treatment available. While animal model studies seemed extremely promising, no success has been achieved in the larger clinical trials with human FXS patients. This short review describes the steps that have been taken in the development of a targeted treatment for FXS. Possible reasons for the lack of translation between animal models and human FXS patients are being explored and solutions are being proposed. The FXS story illustrates pitfalls and possibilities in translational research, that might especially be applicable for other neurodevelopmental disorders as well.


FMR1; fragile X syndrome; Fmr1 KO mouse; mGluR5; GABA; clinical trial; outcome measure

Article Metrics:

  1. Hunter J, Rivero-Arias O, Angelov A, Kim E, Fotheringham I, Leal J. Epidemiology of fragile X syndrome: A systematic review and meta-analysis. Am J Med Genet A. 2014;164(7):1648-58.
  2. Rauch A, Hoyer J, Guth S, Zweier C, Kraus C, Becker C, et al. Diagnostic yield of various genetic approaches in patients with unexplained developmental delay or mental retardation. Am J Med Genet A. 2006;140(19):2063-74.
  3. Hersh JH, Saul RA, Saal HM, Braddock SR, Enns GM, Gruen JR, et al. Clinical Report-Health Supervision for Children With Fragile X Syndrome. Pediatrics. 2011;127(5):994-1006.
  4. Kidd SA, Lachiewicz A, Barbouth D, Blitz RK, Delahunty C, McBrien D, et al. Fragile X Syndrome: A Review of Associated Medical Problems. Pediatrics. 2014;134(5):995-1005.
  5. Verkerk AJ, Pieretti M, Sutcliffe JS, Fu YH, Kuhl DP, Pizzuti A, et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell. 1991;65(5):905-14.
  6. Esch CE, Zeidler S, Willemsen R. Translational endpoints in fragile x syndrome. Neurosci Biobehav Rev. 2014;46:256-69.
  7. Gross C, Hoffmann A, Bassell GJ, Berry-Kravis EM. Therapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and Back. Neurotherapeutics. 2015;12(3):584-608.
  8. Ligsay A, Hagerman RJ. Review of targeted treatments in fragile X syndrome. Intractable Rare Dis Res. 2016;5(3):158-67.
  9. Berry-Kravis EM, Lindemann L, Jonch AE, Apostol G, Bear MF, Carpenter RL, et al. Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome. Nat Rev Drug Discov. 2018;17(4):280-99.
  10. Kazdoba TM, Leach PT, Silverman JL, Crawley JN. Modeling fragile X syndrome in the Fmr1 knockout mouse. Intractable Rare Dis Res. 2014;3(4):118-33.
  11. Zeidler S, Hukema RK, Willemsen R. The quest for targeted therapy in fragile X syndrome. Expert Opin Ther Targets. 2015;19(10):1277-81.
  12. van der Worp HB, Howells DW, Sena ES, Porritt MJ, Rewell S, O'Collins V, et al. Can animal models of disease reliably inform human studies? PLoS Med. 2010;7(3):e1000245.
  13. Budimirovic DB, Berry-Kravis E, Erickson CA, Hall SS, Hessl D, Reiss AL, et al. Updated report on tools to measure outcomes of clinical trials in fragile X syndrome. J Neurodev Disord. 2017;9:14.
  14. Castren E, Elgersma Y, Maffei L, Hagerman R. Treatment of neurodevelopmental disorders in adulthood. J Neurosci. 2012;32(41):14074-9.
  15. Zeidler S, de Boer H, Hukema RK, Willemsen R. Combination Therapy in Fragile X Syndrome; Possibilities and Pitfalls Illustrated by Targeting the mGluR5 and GABA Pathway Simultaneously. Front Mol Neurosci. 2017;10:368.
  16. Pacey LK, Tharmalingam S, Hampson DR. Subchronic Administration and Combination Metabotropic Glutamate and GABAB Receptor Drug Therapy in Fragile X Syndrome. J Pharmacol Exp Ther. 2011;338(3):897-905.
  17. Lim CS, Hoang ET, Viar KE, Stornetta RL, Scott MM, Zhu JJ. Pharmacological rescue of Ras signaling, GluA1-dependent synaptic plasticity, and learning deficits in a fragile X model. Genes Dev. 2014;28(3):273-89.
  18. Kraan CM, Godler DE, Amor DJ. Epigenetics of fragile X syndrome and fragile X-related disorders. Dev Med Child Neurol. 2018.